Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease
Abstract
After decades of research and clinical trials there is still no cure for Alzheimer's disease (AD). While impaired clearance of amyloid beta (Aβ) peptides is considered as one of the major causes of AD, it was recently complemented by a potential role of other toxic amyloidogenic species. Insulin-degrading enzyme (IDE) is the proteolytic culprit of various β-forming peptides, both extracellular and intracellular. On the basis of demonstrated allosteric activation of IDE against Aβ, it is possible to propose a new strategy for the targeted IDE-based cleansing of different toxic aggregation-prone peptides. Consequently, specific allosteric activation of IDE coupled with state-of-the-art compound delivery and CRISP-Cas9 technique of transgene insertion can be instrumental in the fight against AD and related neurodegenerative maladies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Aβ degradation is ensured by proteases such as cathepsin and insulin-degrading enzyme (IDE), which cleave Aβ into smaller soluble fragments.
“The Aβ degradation is ensured by some proteases, such as cathepsin and the insulin-degrading enzyme (IDE), which cleave the Aβ into smaller soluble fragments (Miners et al., 2011; Kurochkin et al., 2018).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Kurochkin et al., 2018
The citation lists haven’t been fetched yet
References 110 · Cited by 185
- Authors
- Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N.
- Affiliations
- Sysmex (Japan) (JP)
- Agency for Science, Technology and Research (SG)
- Corresponding author
- Berezovsky, Igor N.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 39
- Issue
- 1
- Pages
- 49-58
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2767842669
- Cited by
- 185
- References
- 110
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 19 · 2023: 24 · 2022: 36 · 2021: 26 · 2020: 23 · 2019: 13 · 2018: 14
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in Pharmacological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Biomedical Research Council, Agency for Science, Technology, and Research (A*STAR)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- insulin-degrading enzyme, Alzheimer's disease, amyloid-beta, amyloid fibril formation, allosteric activation, CRISPR/Cas9 genome editing, transgene integration, neurodegenerative diseases
- MeSH terms
- Allosteric Regulation, Alzheimer Disease, Amyloid, Animals, Humans, Insulysin, Mutation, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
